Eli Lilly: The Top Large Cap Bio Pharma Pick

Drug analyst Colin Bristow says Eli Lilly is expected to have dominant market share by the end of the decade. The company's revenue from obesity drugs are expected to double in two to three years, he says. He has a price target that last I checked implied about 8% upside from recent levels.